A year after enduring a stinging FDA rejection, Merck has convinced the agency to sign off on lower doses of its suvorexant, a novel sleep drug once predicted to become a blockbuster.

…read more

Source: Merck wins FDA nod for a weaker form of its embattled sleep drug


0 No comments